Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors

A. Madani, K. Kemmer, C. Sweeney, C. Corless, T. Ulbright, M. Heinrich, L. Einhorn

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Background: The majority of patients with germ-cell tumors (GCTs) are curable with standard therapy. The molecular differences between curable and incurable disease are unknown. We have studied the expression of KIT and the epidermal growth factor receptor (EGFR) to determine their incidence in chemorefractory disease. Patients and methods: We retrospectively analyzed 23 patients with chemorefractory non-seminomatous GCTs (15 late relapse and eight transformed teratomas). None of these 23 patients were cured by their initial chemotherapy and/or surgery. Immunohistochemical analysis of KIT and EGFR was performed on the most recently available specimen from a metastatic site. PCR amplimers of KIT exon 17 were screened for mutations by a combination of denaturing high-performance liquid chromatography and direct sequencing. Results: KIT was expressed (≥10% of the tumor displaying membranous or cytoplasmic staining) in 11 of 23 GCT patients [48%; 95% confidence interval (CI) 26% to 68%]. There were no activating KIT mutations in the phosphoryltransferase domain (exon 17) in 21 patients analyzed. EGFR was expressed (1+ to 3+) in 15 of 23 GCT patients (65%; 95% CI 41% to 82%). Conclusions: KIT and EGFR are expressed in a significant proportion of refractory GCTs. The significance of these findings will be determined by ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)873-880
Number of pages8
JournalAnnals of Oncology
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2003

Keywords

  • c-Kit
  • EGFR
  • Germ-cell tumor
  • Refractory
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors'. Together they form a unique fingerprint.

  • Cite this